Alexander Gregory R. 4

What Happened

• Syra Health CEO Alexander Gregory R. received two compensation awards on Jan 5, 2026: 110,537 restricted stock units (RSUs) granted at $0 and a 257,920-share derivative award (likely stock options) granted at $0. These were awards (not purchases), so no cash changed hands. The derivative award is reported separately as a "derivative" acquisition rather than a share purchase or option exercise.

Key Details

• Transaction date: 2026-01-05; Filing date (Form 4): 2026-02-03 (filed late relative to the usual 2-business-day reporting requirement).
• Grant prices: $0.00 for both awards (standard for compensation grants).
• Shares reported acquired: 110,537 (RSUs) and 257,920 (derivative award).
• Shares owned after transaction: Not specified in the provided filing summary.
• Vesting notes: F1 — RSUs: 20% vest one year after grant, remainder vests equally over four years on each anniversary beginning one year after grant. F2 — Options/derivative: 20% vest after one year, remainder vests equally over four years on each anniversary beginning one year after grant.
• Other: No indication in the filing that awards were exercised, sold, part of a 10b5-1 plan, or subject to tax-withholding sales.

Context

• These grants are compensation-related awards and are different from insider purchases (which can signal direct buying interest). They vest over multiple years per the footnotes, so the economic benefit to the CEO is tied to continued service and future vesting. The late filing (nearly a month after the grant) is procedural and may attract investor attention for timeliness/compliance reasons but does not itself indicate trading intent.